Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of long-acting HM10560A in adult growth hormone deficiency
2011-001826-61Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of efpegsomatropin in adult onset growth hormone deficiency (AGHD) (3 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Change in IGF-I over time by dose. Started May 2011; status: completed.
02
Drugs
efpegsomatropin
03
Conditions
adult onset growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on 2011-001826-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001826-61.